There are 2137 resources available
1032P - Safety data from stratum D of the phase I INSIGHT platform trial evaluating feasibility of IMP321 (LAG-3Ig protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumour entities
Presenter: Thorsten Goetze
Session: E-Poster Display
Resources:
Abstract
1033P - The phase I INSIGHT platform trial: Strata A and B evaluating feasibility of intratumoral and intraperitoneal IMP321 (soluble LAG-3 protein, eftilagimod alpha) in advanced solid tumours
Presenter: Salah-Eddin Al-Batran
Session: E-Poster Display
Resources:
Abstract
1034P - Camrelizumab in the treatment of patients with local advanced/metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, prospective, cohort study
Presenter: Qun Zhu
Session: E-Poster Display
Resources:
Abstract
1035P - Effect of gut microbiota on immunotherapy of advanced NSCLC
Presenter: Feiyu Zhang
Session: E-Poster Display
Resources:
Abstract
1036P - Patients’ sex and PD-L1 expression jointly associated with overall survival benefits of immune checkpoint inhibitors in cancer
Presenter: Yunfang Yu
Session: E-Poster Display
Resources:
Abstract
1037P - Tumour mutational burden and HLA diversity by TruSight oncology 500 (TSO500) next generation sequencing panel and clinical outcome in non-small cell lung cancer
Presenter: Kristof Cuppens
Session: E-Poster Display
Resources:
Abstract
1038P - Impact of metastatic location on immune-checkpoint inhibitors efficacy in patients with different solid tumours
Presenter: Madeleine Maugeais
Session: E-Poster Display
Resources:
Abstract
1039P - Analysis of predictive and prognostic soluble biomarkers in advanced non-small cell lung cancer (NSCLC) patients treated with anti-PD1/PDL1
Presenter: Sandra Gallach Garcia
Session: E-Poster Display
Resources:
Abstract
1040P - The prognostic role of “drug score” on the outcome of advanced cancer patients treated with immune checkpoint inhibitors
Presenter: Fabiana Perrone
Session: E-Poster Display
Resources:
Abstract
1042P - Objective response rate as an intermediate surrogate endpoint to predict overall survival at 12 months
Presenter: Won-hee Yoon
Session: E-Poster Display
Resources:
Abstract